Retatrutide vs Survodutide
Triple Agonist (GLP-1/GIP/Glucagon) · Dual Agonist (GLP-1/Glucagon)
Here is how these two compounds compare, based on published research, not marketing claims.
Retatrutide
An investigational triple-receptor agonist (GLP-1, GIP, glucagon) with the largest mean body weight reduction reported in any controlled clinical trial; Phase III, not yet FDA-approved.
Survodutide
An investigational GLP-1 plus glucagon dual agonist with Phase II liver fat data leading the obesity peptide class; Phase III, not yet FDA-approved.
Retatrutide
131 studies
12 human trials
Not FDA-Approved
Survodutide
87 studies
8 human trials
Not FDA-Approved
What it does
Retatrutide
A triple-receptor agonist studied for weight management and type 2 diabetes. Activates three appetite and metabolism receptors at once: GLP-1, GIP, and glucagon. Trial data shows the largest weight-loss effect of any peptide therapeutic published to date. Currently in Phase III development; not yet FDA-approved.
Survodutide
An investigational dual-receptor agonist studied for weight management and metabolic liver disease. Activates two receptors at once: GLP-1 (the appetite-control receptor semaglutide uses) and glucagon (a separate receptor that increases energy expenditure and helps the liver oxidize stored fat). Phase II trials showed up to 19% mean body weight reduction at 46 weeks. Currently in Phase III development; not yet FDA-approved.
How it works
Retatrutide
An engineered peptide that binds three receptor systems simultaneously. The GLP-1 side reduces appetite and slows gastric emptying (the mechanism semaglutide and tirzepatide use). The GIP side adds enhanced fat metabolism (the mechanism tirzepatide adds beyond GLP-1). The glucagon side adds increased energy expenditure and hepatic fat oxidation, the mechanism that distinguishes retatrutide from earlier GLP-1 medications. The combined triple action appears to drive the larger weight-loss numbers seen in published trials.
Survodutide
An engineered peptide that binds two receptor systems at once. The GLP-1 side reduces appetite and slows gastric emptying (the same mechanism semaglutide uses). The glucagon side adds increased energy expenditure (more calories burned at rest) and increased hepatic fat oxidation (the liver burning stored fat for fuel). The glucagon mechanism is what differentiates survodutide from GLP-1-only medications and drives the strong liver fat reduction seen in published trials.
How often
Retatrutide
Trial protocols across the TRIUMPH Phase III program use once-weekly subcutaneous injection. The TRIUMPH-4 trial ran 68 weeks; the Phase II obesity trial (Jastreboff et al. 2023, NEJM) ran 48 weeks; the Phase II type 2 diabetes trial (Rosenstock et al. 2023, Lancet) tested four ascending doses against placebo. Six remaining TRIUMPH Phase III trials are still reading out as of 2026. Retatrutide is not yet FDA-approved; clinical availability is restricted to investigational protocols.
Survodutide
Trial protocols use once-weekly subcutaneous injection. The Phase II obesity trial (Le Roux et al. 2024, Lancet) tested four ascending doses over 46 weeks. The SYNCHRONIZE Phase III obesity program is currently underway, alongside parallel Phase III trials for MASH (metabolic dysfunction-associated steatohepatitis) and type 2 diabetes. Survodutide is not yet FDA-approved; clinical availability is restricted to investigational protocols.
How strong
Retatrutide
Phase II trials reported up to 24.2% mean body weight reduction at the 12 mg dose over 48 weeks (Jastreboff et al. 2023, NEJM). The TRIUMPH-4 Phase III trial reported 28.7% mean body weight reduction at the 12 mg dose over 68 weeks in adults with obesity and knee osteoarthritis, the largest weight-loss outcome reported in a controlled clinical trial. Six remaining TRIUMPH Phase III trials are still reading out across additional populations.
Survodutide
Phase II reported up to 19% mean body weight reduction at the highest dose over 46 weeks (Le Roux et al. 2024, Lancet). The same trial reported 47% relative liver fat reduction at the highest dose, the strongest liver fat data among current Phase II/III obesity peptides. Phase III readouts from the SYNCHRONIZE program are expected through 2027.
Main tradeoff
Retatrutide
Trial data shows retatrutide producing larger mean body weight reduction than tirzepatide in Phase II indirect comparison and TRIUMPH-4 Phase III. The structural difference is FDA approval status: tirzepatide is FDA-approved and clinically available today; retatrutide remains in Phase III development. Less long-term safety data overall because the compound is the newer of the two. TRIUMPH-4 reported a new dysesthesia (abnormal skin sensation) safety signal at higher doses requiring monitoring across the remaining TRIUMPH program. Bone mineral density has not yet been reported in retatrutide trials; whether the class-shared bone-loss-with-weight-loss signal observed in semaglutide and tirzepatide users (Liu et al. 2026) extends to retatrutide is empirically open.
Survodutide
Phase II data shows survodutide weight-loss effects similar to semaglutide and slightly below tirzepatide; the differentiator is the glucagon component's impact on liver fat. The structural difference is regulatory status: semaglutide and tirzepatide are FDA-approved; survodutide is in Phase III development. Less long-term safety data overall because the compound is investigational. The glucagon receptor's contribution to glucose homeostasis differs from pure GLP-1 agonism; whether this affects glycemic control over multi-year use is empirically open.
Best for
Retatrutide
- Research interest in next-generation triple-receptor agonist mechanism
- Awaiting FDA approval for clinical use; monitoring the TRIUMPH Phase III program for population coverage and safety profile
- Patients in TRIUMPH or other retatrutide clinical trials under investigator supervision
Survodutide
- Research interest in dual-receptor (GLP-1 + glucagon) mechanism
- Particular interest in metabolic dysfunction-associated steatohepatitis (MASH) where the glucagon pathway shows strong Phase II liver fat data
- Patients in SYNCHRONIZE or other survodutide clinical trials under investigator supervision
How to choose
A good fit for Retatrutide
- Research interest in the next-generation triple-receptor mechanism (GLP-1 + GIP + glucagon)
- Particular interest in maximum weight loss outcomes (TRIUMPH-4 Phase III reported 28.7 percent reduction at 12 mg)
- Monitoring the TRIUMPH Phase III program for clinical adoption when FDA approval lands
- Participation in retatrutide clinical trials under investigator supervision
A good fit for Survodutide
- Research interest in metabolic dysfunction-associated steatohepatitis (MASH) where survodutide's Phase II liver fat data leads the class
- Particular interest in the dual GLP-1 plus glucagon mechanism without GIP
- Monitoring the SYNCHRONIZE Phase III program for clinical adoption when FDA approval lands
- Participation in survodutide clinical trials under investigator supervision
Consider both across time
Retatrutide and survodutide are both investigational compounds with overlapping mechanisms: both add the glucagon receptor to GLP-1 activation. The structural difference is GIP. Retatrutide adds GIP as a third receptor, producing the largest weight-loss numbers reported in any clinical trial; survodutide pairs GLP-1 with glucagon alone and produces the strongest Phase II liver fat reduction in the class. Neither is clinically available. For each compound's comparison against the FDA-approved standard, see Semaglutide vs Survodutide and Tirzepatide vs Retatrutide.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GLP-1 Receptor
- GIP Receptor
- Glucagon Receptor
- GLP-1 Receptor activates Appetite Suppression
- GIP Receptor activates Insulin Sensitivity
- Glucagon Receptor activates Hepatic Fat Oxidation; Dual GLP-1 + Glucagon Signaling connects to Hepatic Fat Oxidation
- Appetite Suppression connects to Metabolic Regulation; Insulin Sensitivity connects to Metabolic Regulation
- Hepatic Fat Oxidation connects to Energy Expenditure
- GLP-1 Receptor activates Dual GLP-1 + Glucagon Signaling; Glucagon Receptor activates Dual GLP-1 + Glucagon Signaling
- Dual GLP-1 + Glucagon Signaling connects to Appetite + Energy Expenditure
- Appetite + Energy Expenditure connects to Weight + Liver Outcomes; Hepatic Fat Oxidation connects to Weight + Liver Outcomes
Retatrutide activates three receptors at once: GLP-1, GIP, and glucagon. The triple action drives the largest weight-loss numbers in published trials.
Survodutide activates both GLP-1 and glucagon receptors at once. The dual mechanism focuses on weight reduction plus hepatic fat oxidation without GIP.
Research Evidence
Both compounds sit at PSI's Human Trials tier with active Phase III programs. Retatrutide's Phase II obesity trial (Jastreboff et al. 2023, NEJM) reported 24.2 percent mean body weight reduction at 12 mg over 48 weeks; the TRIUMPH-4 Phase III trial in 2026 reported 28.7 percent mean body weight reduction at 12 mg over 68 weeks in adults with obesity and knee osteoarthritis. Survodutide's Phase II obesity trial (Le Roux et al. 2024, Lancet) reported 19 percent mean body weight reduction at 46 weeks plus 47 percent relative liver fat reduction at the highest dose. Six remaining TRIUMPH Phase III trials and the SYNCHRONIZE Phase III obesity program are still reading out across additional populations. For research focused on maximum weight loss, retatrutide's published data leads; for research focused on metabolic liver disease, survodutide's mechanism leads.
- 1.
For maximum weight loss based on Phase 2 data, retatrutide showed higher numbers.
- 2.
For liver fat specifically, survodutide's glucagon component has shown particular promise for MASH.
- 3.
For a simpler mechanism with potentially fewer unknowns, survodutide targets fewer receptors.
- 4.
For both compounds, Phase 3 results will determine the real-world picture.
Key Limitations
- •Both are in Phase 3. Results pending.
- •No head-to-head trial exists or is planned.
- •Phase 2 weight loss numbers do not predict Phase 3 outcomes.
- •Safety profiles will only be clear after larger, longer trials.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Retatrutide
"Retatrutide will make Ozempic and Mounjaro obsolete"
Plausible but premature
"The triple agonist mechanism is a game-changer"
Supported by evidence
"Retatrutide causes a weird tingling skin sensation"
Supported by evidence
Safety Comparison
Both compounds have Phase II and limited Phase III safety data showing GI side effects similar to the GLP-1 class (nausea, vomiting, diarrhea, transient and dose-dependent). Retatrutide's TRIUMPH-4 Phase III trial reported a new dysesthesia (abnormal skin sensation) safety signal at higher doses, requiring continued monitoring across the remaining TRIUMPH program; survodutide trials have not reported a comparable signal to date. The glucagon receptor's contribution to glucose homeostasis introduces an open question about long-term glycemic control for both compounds that pure GLP-1 medications do not have. Whether the class-shared bone-loss-with-weight-loss signal observed in semaglutide and tirzepatide users (Liu et al. 2026, J Clin Endocrinol Metab) extends to dual or triple agonists like survodutide and retatrutide is empirically open.
Retatrutide
Phase 2 showed GI side effects consistent with the class. Phase 3 in progress. Long-term safety unknown.
Survodutide
Phase 2 showed manageable GI side effects. Phase 3 in progress.
What the Research Suggests
Retatrutide has the more impressive Phase 2 data. Survodutide has the simpler mechanism. Both could be approved. Both could disappoint. The race is far from over.